The following AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey, and AmeriHealth Administrators policies went into notification on November 1, 2022, and will become effective on January 1, 2023:
- 00.10.41k: Telemedicine
- 05.00.69c: Home-Use Light Box Therapy for the Treatment of Seasonal Affective Disorder (SAD)
- 05.00.80c: Cranial Electrotherapy Stimulation
- 06.02.30g: Pharmacogenetic Testing to Determine Drug Sensitivity
- 06.02.44p: Presumptive and Definitive Drug Testing in Substance Abuse and Pain Management Treatments
- 06.02.55a: Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or Antiepileptic
- 07.03.07h: Medical Evaluation and Management for Attention-Deficit Hyperactivity Disorder (ADHD)
- 07.03.22e: Transcranial Magnetic Stimulation
- 08.01.37b: Maintenance Treatment of Opioid or Alcohol Dependence Disorder
- 08.01.80a: Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®)
- 11.15.16r: Vagus Nerve Stimulation (VNS)
- 11.15.20q: Deep Brain Stimulation (DBS)
- 12.01.01bg: Experimental/Investigational
- 12.04.04b: Acute Care Facility Inpatient Transfers
- 14.00.01: Electroconvulsive therapy (ECT)
- 14.00.02: Psychological Testing
- 14.00.03: Applied Behavioral Analysis (ABA) for the Treatment of Autism Spectrum Disorder (ASD)
For more information, please refer to the policy notifications published on November 1, 2022.